Clinical focus and interest:
Professor Bosch is one of the most internationally reputed leaders in chronic lymphocytic leukemia (CLL). He conducts both clinical and basic research in CLL and other lymphoproliferative disorders, particularly focusing on the molecular pathogenesis of CLL and the development of novel therapeutic approaches. Since 1995 he has been involved in the development of clinical trials in CLL, adding several contributions to the prognosis, assessment and treatment of CLL.
Professor Bosch graduated from Medical School in the University of Barcelona in 1988. In 1997 he was awarded a PhD by the University of Barcelona for his research about the over-expression of cyclin D1 in chronic lymphoproliferative disorders under the supervision of Professor Elias Campo. He subsequently carried out a two-year postdoctoral post in the laboratory of Professor Riccardo Dalla-Favera at the Institute of Cancer Genetics, Columbia University, New York. He moved back to the Hospital Clinic Barcelona in 2000 where he continued his research in CLL.
In September 2009, Professor Bosch became Head of the Department of Hematology and Director of the Experimental Hematology Laboratory at the University Hospital Vall d’Hebron in Barcelona.
Professor Bosch is currently chairing the Spanish CLL Working Group (GELLC), responsible for the development of Spanish CLL clinical trials. He has published more than two hundred papers in peer-reviewed journals including high-impact journals such as The New England Journal of Medicine, Nature Medicine, Cancer Cell, Blood, Journal of Clinical Oncology, and Leukemia. In addition, he has authored or co-authored several reviews and book chapters on the subject of CLL and other lymphoproliferative disorders.